This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Dayton Therapeutics
In 2020, the E3 Life team established Dayton Therapeutics to acquire the late-stage developmental prostate cancer pharmaceutical, Satraplatin. We re-developed it for use against rare lymphomas.
Based on in-vitro lab research studies, we identified novel molecular mechanisms and biomarkers (published in a peer-reviewed journal) and filed for patents. Satraplatin’s molecular and clinical signature allowed us to identify primary CNS lymphoma (PCNSL) as the most suitable target indication, for which we established an appropriate clinical, regulatory, and manufacturing pathway.
In 2024, Satraplatin was successfully sold to a rapidly growing European specialty pharmaceutical company.